Vitamin D and cardiovascular disease

Current Treatment Options in Cardiovascular Medicine

Volumn 14, Issue 4, 2012, Pages 414-424

  Danik, Jacqueline S ^a   Manson, JoAnn E ^a  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

Cardiovascular disease; Diabetes; Diet; Hypertension; Omega 3 fatty acids; Prevention; Vitamin D

Indexed keywords

CALCIUM; COLECALCIFEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; OMEGA 3 ACID ETHYL ESTER; PLACEBO; VITAMIN D;

BLOOD PRESSURE; CANCER PREVENTION; CARDIOMETABOLIC RISK; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; DIABETES MELLITUS; DIETARY INTAKE; HEART DISEASE; HUMAN; HYPERTENSION; INFLAMMATION; INSULIN RESISTANCE; MYALGIA; NON INSULIN DEPENDENT DIABETES MELLITUS; NUTRITIONAL REQUIREMENT; OBSERVATIONAL STUDY; POSTMENOPAUSE; PREVALENCE; REVIEW; STROKE; TREATMENT DURATION; UNITED STATES; VITAMIN BLOOD LEVEL; VITAMIN D DEFICIENCY; VITAMIN INTAKE; VITAMIN SUPPLEMENTATION;

EID: 84865697490     PISSN: 10928464     EISSN: 15343189     Source Type: Journal    
DOI: 10.1007/s11936-012-0183-8     Document Type: Review

References (104)

1. Ross AC,Manson JE, Abrams SA, et al. The 2011 report on dietary reference intakes for calcium and vitamin d from the institute of medicine: What clinicians need to know. J Clin Endocrinol Metab. 2011;96(1):53-8. This paper provides the clinician with a review of the current dietary guidelines.
2. Institute of Medicine. Dietary reference intakes for calcium and vitamin D. Washington: National Academies Press; 2011.
3. Chung M, Balk EM, Brendel M, et al. Vitamin D and calcium: A systematic review of health outcomes. Evidence report/technology assessment no.183. Agency for Healthcare Research and Quality. Rockville, MD Aug 2009. This paper is the AHRQ's systemic review of the literature.
4. Norman AW. From vitamin D to hormone D: Fundamentals of the vitaminDendocrine systemessential for good health. Am J Clin Nutr. 2008;88(2):491S-9S.
5. Holick MF. Vitamin D deficiency. N Engl J Med. 2007;357(3):266-81.
6. Chun RF, Adams JS, Hewison M. Back to the future: A new look at 'old' vitamin D. J Endocrinol. 2008;198 (2):261-9.
7. Hewison M, Burke F, Evans KN, et al. Extra-renal 25-hydroxyvitamin D3-1[alpha]-hydroxylase in human health and disease. J Steroid Biochem Mol Biol. 2007;103(3-5):316-21. (Pubitemid 46420518)
8. Adams JS, Hewison M. Unexpected actions of vitamin D: New perspectives on the regulation of innate and adaptive immunity. Nat Clin Pract Endocrinol Metab. 2008;4(2):80-90. (Pubitemid 351156900)
9. Zhou S, LeBoff MS, Glowacki J. Vitamin D metabolism and action in human bone marrow stromal cells. Endocrinology. 2010;151(1):14-22.
10. Holick MF, Siris ES, Binkley N, et al. Prevalence of Vitamin D inadequacy among postmenopausal North American women receiving osteoporosis therapy. JClin Endocrinol Metab. 2005;90(6):3215-24. (Pubitemid 41014278)
11. Looker AC, Dawson-Hughes B, Calvo MS, Gunter EW, Sahyoun NR. Serum 25-hydroxyvitamin D status of adolescents and adults in two seasonal subpopulations from NHANES III. Bone. 2002;30(5):771-7. (Pubitemid 34468001)
12. Rosen CJ. Clinical practice. Vitamin D insufficiency. N Engl J Med. 2011;364(3):248-54.
13. Looker AC, Pfeiffer CM, Lacher DA, Schleicher RL, Picciano MF, Yetley EA. Serum 25-hydroxyvitamin D status of the US population: 1988-1994 compared with 2000-2004. Am J Clin Nutr. 2008;88(6):1519-27.
14. Cauley JA, Lacroix AZ, Wu L, et al. Serum 25-hydroxyvitamin D concentrations and risk for hip fractures. Ann Intern Med. 2008;149(4):242-50.
15. Chapuy MC, Arlot ME, Duboeuf F, et al. Vitamin D3 and calcium to prevent hip fractures in the elderly women. N Engl J Med. 1992;327 (23):1637-42.
16. Chapuy MC, Pamphile R, Paris E, et al. Combined calcium and vitamin D3 supplementation in elderly women: Confirmation of reversal of secondary hyperparathyroidism and hip fracture risk: The Decalyos II study. Osteoporos Int. 2002;13 (3):257-64. (Pubitemid 34408194)
17. LeBoff MS, Hawkes WG, Glowacki J, Yu-Yahiro J, Hurwitz S, Magaziner J. Vitamin D-deficiency and post-fracture changes in lower extremity function and falls in women with hip fractures. Osteoporos Int. 2008;19(9):1283-90.
18. LeBoff MS, Kohlmeier L, Hurwitz S, Franklin J, Wright J, Glowacki J. Occult vitamin D deficiency in postmenopausal US women with acute hip fracture. JAMA. 1999;281(16):1505-11. (Pubitemid 29200934)
19. Pieper CF, Colon-Emeric C, Caminis J, et al. Distribution and correlates of serum 25-hydroxyvitamin D levels in a sample of patients with hip fracture. Am J Geriatr Pharmacother. 2007;5(4):335-40.
20. Moore CE, Murphy MM, Holick MF. Vitamin D intakes by children and adults in the United States differ among ethnic groups. J Nutr. 2005;135 (10):2478-85. (Pubitemid 41429611)
21. Harris SS. Vitamin D and African Americans. J Nutr. 2006;136(4):1126-9.
22. Zadshir A, Tareen N, Pan D, Norris K, Martins D. The prevalence of hypovitaminosis D among US adults: Data from the NHANES III. Ethn Dis. Autumn 2005;15(4 Suppl 5):S5-97-101.
23. Harris SS, Dawson-Hughes B. Reduced sun exposure does not explain the inverse association of 25-hydroxyvitamin D with percent body fat in older adults. J Clin Endocrinol Metab. 2007;92(8):3155-7. (Pubitemid 47236385)
24. Martins D, Wolf M, Pan D, et al. Prevalence of cardiovascular risk factors and the serum levels of 25-hydroxyvitamin D in the United States: Data from the Third National Health and Nutrition Examination Survey. Arch Intern Med. 2007;167(11):1159-65. (Pubitemid 46919818)
25. Flegal KM, Carroll MD, Ogden CL, Curtin LR. Prevalence and trends in obesity among US adults, 1999-2008. JAMA. 2010;303(3):235-41.
26. Zittermann A. Vitamin D and disease prevention with special reference to cardiovascular disease. Prog Biophys Mol Biol. 2006;92(1):39-48. (Pubitemid 43831966)
27. Zittermann A, Koerfer R. Vitamin D in the prevention and treatment of coronary heart disease. Curr Opin Clin Nutr Metab Care. 2008;11(6):752-7.
28. Giovannucci E, Liu Y, Hollis BW, Rimm EB. 25-hydroxyvitamin D and risk of myocardial infarction in men: A prospective study. Arch Intern Med. 2008;168(11):1174-80. (Pubitemid 351831400)
29. Wang TJ, Pencina MJ, Booth SL, et al. Vitamin D deficiency and risk of cardiovascular disease. Circulation. 2008;117(4):503-11.
30. Dobnig H, Pilz S, Scharnagl H, et al. Independent association of low serum 25-hydroxyvitamin d and 1,25-dihydroxyvitamin d levels with all-cause and cardiovascular mortality. Arch Intern Med. 2008;168 (12):1340-9. (Pubitemid 351930842)
31. Anderson JL, May HT, Horne BD, et al. Relation of vitamin D deficiency to cardiovascular risk factors, disease status, and incident events in a general healthcare population. Am J Cardiol. 2010;106(7):963-8.
32. Bassuk SS, Manson JE. Does vitamin D protect against cardiovascular disease? J Cardiovasc Transl Res. 2009;2(3):245-50.
33. Melamed ML, Michos ED, Post W, Astor B. 25-hydroxyvitamin D levels and the risk of mortality in the general population. Arch Intern Med. 2008;168 (15):1629-37.
34. Wang L, Manson JE, Song Y, Sesso HD. Systematic review: Vitamin D and calcium supplementation in prevention of cardiovascular events. Ann Intern Med. 2010;152(5):315-23.
35. Avenell A, Maclennan GS, Jenkinson DJ, et al. Longterm follow-up for mortality and cancer in a randomized placebo-controlled trial of vitamin D3 and/ or calcium (RECORD Trial). J Clin Endocrinol Metab. Nov 23 2011.
36. Liu S, Song Y, Ford ES, Manson JE, Buring JE, Ridker PM. Dietary calcium, vitamin D, and the prevalence of metabolic syndrome in middle-aged and older U.S. women. Diabetes Care. 2005;28 (12):2926-32. (Pubitemid 43942926)
37. Wactawski-Wende J, Kotchen JM, Anderson GL, et al. Calcium plus vitaminDsupplementation and the risk of colorectal cancer. N Engl J Med. 2006;354(7):684-96. (Pubitemid 43247139)
38. Jackson RD, LaCroix AZ, Gass M, et al. Calcium plus vitamin D supplementation and the risk of fractures. N Engl J Med. 2006;354(7):669-83. (Pubitemid 43247138)
39. van Etten E, Mathieu C. Immunoregulation by 1,25-dihydroxyvitamin D3: Basic concepts. J Steroid Biochem Mol Biol. 2005;97(1-2):93-101.
40. MiyakoshiH, Aoki T,HirasawaY. Immunological effects of 1alpha-hydroxycholecalciferol (1alpha-OH-D3) and its metabolites. Clin Nephrol. 1981;16(3):119-25.
41. D'Ambrosio D, Cippitelli M, Cocciolo MG, et al. Inhibition of IL-12 production by 1,25-dihydroxyvitamin D3. Involvement of NF-kappaB downregulation in transcriptional repression of the p40 gene. J Clin Invest. 1998;101(1):252-62. (Pubitemid 28058925)
42. Alroy I, Towers TL, Freedman LP. Transcriptional repression of the interleukin-2 gene by vitamin D3: Direct inhibition of NFATp/AP-1 complex formation by a nuclear hormone receptor. Mol Cell Biol. 1995;15(10):5789-99.
43. Muller K, Haahr PM, Diamant M, Rieneck K, Kharazmi A, Bendtzen K. 1,25-Dihydroxyvitamin D3 inhibits cytokine production by human blood monocytes at the post-transcriptional level. Cytokine. 1992;4(6):506-12.
44. van Halteren AG, van Etten E, de Jong EC, Bouillon R, Roep BO, Mathieu C. Redirection of human autoreactive T-cells Upon interaction with dendritic cells modulated by TX527, an analog of 1,25 dihydroxyvitamin D(3). Diabetes. 2002;51(7):2119-25. (Pubitemid 34729016)
45. Penna G, Adorini L. 1 Alpha,25-dihydroxyvitamin D3 inhibits differentiation, maturation, activation, and survival of dendritic cells leading to impaired alloreactive T cell activation. J Immunol. 2000;164(5):2405-11. (Pubitemid 30115468)
46. Griffin MD, Lutz WH, Phan VA, Bachman LA, McKean DJ, Kumar R. Potent inhibition of dendritic cell differentiation and maturation by vitamin D analogs. Biochem Biophys Res Commun. 2000;270(3):701-8. (Pubitemid 30444768)
47. Griffin MD, Lutz W, Phan VA, Bachman LA, McKean DJ, Kumar R. Dendritic cell modulation by 1alpha,25 dihydroxyvitamin D3 and its analogs: A vitamin D receptor-dependent pathway that promotes a persistent state of immaturity in vitro and in vivo. Proc Natl Acad Sci U S A. 2001;98(12):6800-5. (Pubitemid 32538297)
48. White JH. Vitamin D signaling, infectious diseases, and regulation of innate immunity. Infect Immun. 2008;76(9):3837-43.
49. Kendrick J, Targher G, Smits G, Chonchol M. 25-Hydroxyvitamin D deficiency and inflammation and their association with hemoglobin levels in chronic kidney disease. Am J Nephrol. 2009;30(1):64-72.
50. Shea MK, Booth SL, Massaro JM, et al. Vitamin K and vitamin D status: Associations with inflammatory markers in the Framingham Offspring Study. Am J Epidemiol. 2008;167(3):313-20. (Pubitemid 351197593)
51. Schleithoff SS, Zittermann A, Tenderich G, Berthold HK, Stehle P, Koerfer R. Vitamin D supplementation improves cytokine profiles in patients with congestive heart failure: A double-blind, randomized, placebo-controlled trial. Am J Clin Nutr. 2006;83 (4):754-9. (Pubitemid 44713136)
52. Yamauchi Y, Tsunematsu T, Konda S, Hoshino T, Itokawa Y, Hoshizaki H. A double blind trial of alfacalcidol on patients with rheumatoid arthritis (RA). Ryumachi. 1989;29(1):11-24. (Pubitemid 19203991)
53. Andjelkovic Z, Vojinovic J, Pejnovic N, et al. Disease modifying and immunomodulatory effects of high dose 1 alpha (OH) D3 in rheumatoid arthritis patients. Clin Exp Rheumatol. 1999;17(4):453-6. (Pubitemid 29343630)
54. Perez A, Raab R, Chen TC, Turner A, Holick MF. Safety and efficacy of oral calcitriol (1,25-dihydroxyvitamin D3) for the treatment of psoriasis. Br J Dermatol. 1996;134(6):1070-8. (Pubitemid 26183140)
55. Morimoto S, Yoshikawa K, Kozuka T, et al. Treatment of psoriasis vulgaris with oral 1 alpha,25-dihydroxyvitamin D3-report of two cases. J Dermatol. ;14(1):59-62.
56. El-Azhary RA, Peters MS, Pittelkow MR, Kao PC, Muller SA. Efficacy of vitamin D3 derivatives in the treatment of psoriasis vulgaris: A preliminary report. Mayo Clin Proc. 1993;68(9):835-41. (Pubitemid 23266117)
57. Elst EF, Van Suijlekom-Smit LW, Oranje AP. Treatment of linear scleroderma with oral 1,25-dihydroxyvitamin D3 (calcitriol) in seven children. Pediatr Dermatol. 1999;16(1):53-8. (Pubitemid 29102635)
58. Bjorkman MP, Sorva AJ, Tilvis RS. C-reactive protein and fibrinogen of bedridden older patients in a 6-month vitamin D supplementation trial. J Nutr Health Aging. 2009;13(5):435-9.
59. Alborzi P, Patel NA, Peterson C, et al. Paricalcitol reduces albuminuria and inflammation in chronic kidney disease: A randomized double-blind pilot trial. Hypertension. 2008;52(2):249-55.
60. Li YC, Kong J, Wei M, Chen ZF, Liu SQ, Cao LP. 1,25-Dihydroxyvitamin D(3) is a negative endocrine regulator of the renin-angiotensin system. J Clin Invest. 2002;110(2):229-38. (Pubitemid 34787360)
61. Bouillon R, Carmeliet G, Verlinden L, et al. Vitamin D and human health: Lessons from vitamin D receptor null mice. Endocr Rev. 2008;29(6):726-76.
62. Tarcin O, Yavuz DG, Ozben B, et al. Effect of vitamin D deficiency and replacement on endothelial function in asymptomatic subjects. J Clin Endocrinol Metab. 2009;94(10):4023-30.
63. Kahonen M, Nappi S, Jolma P, et al. Vascular influences of calcium supplementation and vitamin Dinduced hypercalcemia in NaCl-hypertensive rats. J Cardiovasc Pharmacol. 2003;42(3):319-28. (Pubitemid 37071687)
64. Wakasugi M, Noguchi T, Inoue M, et al. Vitamin D3 stimulates the production of prostacyclin by vascular smooth muscle cells. Prostaglandins. 1991;42 (2):127-36.
65. Wong MS, Delansorne R, Man RY, Vanhoutte PM. Vitamin D derivatives acutely reduce endotheliumdependent contractions in the aorta of the spontaneously hypertensive rat. Am J Physiol Heart Circ Physiol. 2008;295(1):H289-96.
66. Zittermann A, Koerfer R. Protective and toxic effects of vitamin D on vascular calcification: Clinical implications. Mol Aspects Med. 2008;29 (6):423-32.
67. Zittermann A, Schleithoff SS, Gotting C, et al. Poor outcome in end-stage heart failure patients with low circulating calcitriol levels. Eur J Heart Fail. 2008;10 (3):321-7.
68. Zhou C, Lu F, Cao K, Xu D, Goltzman D, Miao D. Calcium-independent and 1,25(OH)2D3-dependent regulation of the renin-angiotensin system in 1alphahydroxylase knockout mice. Kidney Int. 2008;74 (2):170-9. (Pubitemid 351915078)
69. Qiao G, Kong J, Uskokovic M, Li YC. Analogs of 1alpha,25-dihydroxyvitamin D(3) as novel inhibitors of renin biosynthesis. J Steroid Biochem Mol Biol. 2005;96(1):59-66. (Pubitemid 41080519)
70. Deb DK, Chen Y, Zhang Z, et al. 1,25-Dihydroxyvitamin D3 suppresses high glucose-induced angiotensinogen expression in kidney cells by blocking the NF-{kappa}B pathway. Am J Physiol Renal Physiol. 2009;296(5):F1212-8.
71. Freundlich M, Quiroz Y, Zhang Z, et al. Suppression of renin-angiotensin gene expression in the kidney by paricalcitol. Kidney Int. 2008;74(11):1394-402.
72. Resnick LM, Muller FB, Laragh JH. Calcium-regulating hormones in essential hypertension. Relation to plasma renin activity and sodium metabolism. Ann Intern Med. 1986;105(5):649-54. (Pubitemid 17176965)
73. Burgess ED, Hawkins RG, Watanabe M. Interaction of 1,25-dihydroxyvitamin D and plasma renin activity in high renin essential hypertension. Am J Hypertens. 1990;3(12 Pt 1):903-5.
74. Sugden JA, Davies JI, Witham MD, Morris AD, Struthers AD. Vitamin D improves endothelial function in patients with type 2 diabetes mellitus and low vitamin D levels. Diabet Med. 2008;25(3):320-5. (Pubitemid 351322698)
75. Shapses SA, Manson JE. Vitamin D and prevention of cardiovascular disease and diabetes: Why the evidence falls short. JAMA. 2011;305(24):2565-6.
76. Cade C, Norman AW. Vitamin D3 improves impaired glucose tolerance and insulin secretion in the vitamin D-deficient rat in vivo. Endocrinology. ;119(1):84-90.
77. Chertow BS, Sivitz WI, Baranetsky NG, Clark SA, Waite A, Deluca HF. Cellular mechanisms of insulin release: The effects of vitamin D deficiency and repletion on rat insulin secretion. Endocrinology. ;113(4):1511-8.
78. Ismail A, Namala R. Impaired glucose tolerance in vitamin D deficiency can be corrected by calcium. J Nutr Biochem. 2000;11(3):170-5. (Pubitemid 30163091)
79. Nyomba BL, Bouillon R, De Moor P. Influence of vitamin D status on insulin secretion and glucose tolerance in the rabbit. Endocrinology. 1984;115 (1):191-7. (Pubitemid 14086809)
80. Chiu KC, Chu A, Go VL, Saad MF. Hypovitaminosis D is associated with insulin resistance and beta cell dysfunction. Am J Clin Nutr. 2004;79(5):820-5. (Pubitemid 41103882)
81. Scragg R, Holdaway I, Singh V, Metcalf P, Baker J, Dryson E. Serum 25-hydroxyvitamin D3 levels decreased in impaired glucose tolerance and diabetes mellitus. Diabetes Res Clin Pract. 1995;27(3):181-8.
82. Liu E, Meigs JB, Pittas AG, et al. Plasma 25-hydroxyvitamin d is associated with markers of the insulin resistant phenotype in nondiabetic adults. J Nutr. 2009;139(2):329-34.
83. Forouhi NG, Luan J, Cooper A, Boucher BJ, Wareham NJ. Baseline serum 25-hydroxy vitamin d is predictive of future glycemic status and insulin resistance: The Medical Research Council Ely Prospective Study 1990-2000. Diabetes. 2008;57(10):2619-25.
84. Pittas AG, Lau J, Hu FB, Dawson-Hughes B. The role of vitamin D and calcium in type 2 diabetes. A systematic review and meta-analysis. J Clin Endocrinol Metab. 2007;92(6):2017-29. (Pubitemid 46997093)
85. Avenell A, Cook JA, MacLennan GS, McPherson GC. Vitamin D supplementation and type 2 diabetes: A substudy of a randomised placebo-controlled trial in older people (RECORD trial, ISRCTN 51647438). Age Ageing. 2009;38(5):606-9.
86. von Hurst PR, Stonehouse W, Coad J. Vitamin D supplementation reduces insulin resistance in South Asian women living in New Zealand who are insulin resistant and vitamin D deficient -a randomised, placebo-controlled trial. Br J Nutr. 2010;103(4):549-55.
87. Zittermann A, Frisch S, Berthold HK, et al. Vitamin D supplementation enhances the beneficial effects of weight loss on cardiovascular disease risk markers. Am J Clin Nutr. 2009;89(5):1321-7.
88. Pittas AG, Harris SS, Stark PC, Dawson-Hughes B. The effects of calcium and vitamin D supplementation on blood glucose and markers of inflammation in nondiabetic adults. Diabetes Care. 2007;30 (4):980-6. (Pubitemid 46556596)
89. Shankar A, Sabanayagam C, Kalidindi S. Serum 25-hydroxyvitamin d levels and prediabetes among subjects free of diabetes. Diabetes Care. 2011;34 (5):1114-9.
90. Ahmed W, Khan N, Glueck CJ, et al. Low serum 25 (OH) vitaminDlevels (G32 ng/mL) are associated with reversible myositis-myalgia in statin-treated patients. Transl Res J Lab Clin Med. 2009;153(1):11-6.
91. Bell DS. Resolution of statin-induced myalgias by correcting vitamin D deficiency. South Med J. 2010;103(7):690-2.
92. Lee P, Greenfield JR, Campbell LV. Vitamin D insufficiency -a novel mechanism of statin-induced myalgia? Clin Endocrinol (Oxf). 2009;71(1):154-5.
93. Drocourt L, Ourlin JC, Pascussi JM, Maurel P, Vilarem MJ. Expression of CYP3A4, CYP2B6, and CYP2C9 is regulated by the vitamin D receptor pathway in primary human hepatocytes. J Biol Chem. 2002;277(28):25125-32. (Pubitemid 34951818)
94. Thummel KE, Brimer C, Yasuda K, et al. Transcriptional control of intestinal cytochrome P-4503A by 1alpha,25-dihydroxy vitamin D3. Mol Pharmacol. 2001;60(6):1399-406. (Pubitemid 33144911)
95. Bhattacharyya S, Bhattacharyya K, Maitra A. Possible mechanisms of interaction between statins and vitamin D. QJM Mon J Assoc Physicians. 2012;105 (5):487-91.
96. Defay R, Astruc ME, Roussillon S, Descomps B, Crastes de Paulet A. DNA synthesis and 3-hydroxy-3-methylglutaryl CoA reductase activity in PHA stimulated human lymphocytes: A comparative study of the inhibitory effects of some oxysterols with special reference to side chain hydroxylated derivatives. Biochem Biophys Res Commun. 1982;106(2):362-72. (Pubitemid 13214624)
97. Bittner V, Wenger N, Waters D, DeMicco DA, Messig M, LaRosa J. Vitamin D levels are not related to myalgias in statin-treated patients with stable coronary disease. J Am Coll Cardiol. 2010;55(Abstract. A177.E1659).
98. Manson JE, Bassuk SS, Lee IM, et al. The VITamin D and OmegA-3 TriaL (VITAL): Rationale and design of a large randomized controlled trial of vitamin D and marine omega-3 fatty acid supplements for the primary prevention of cancer and cardiovascular disease. Contemp Clin Trials. 2012;33(1):159-71. This paper provides a detailed rationale of the VITAL trial.
99. American Cancer Society. Cancer facts & figures for African AMericans 2009-2010. Atlanta: American Cancer Society; 2009.
100. Institute of Medicine Food and Nutrition Board. Dietary reference intakes: Calcium, phosphorous, magnesium vitamin D and fluoride. Washington: National Academies Press; 1999.
101. Bischoff-Ferrari HA, Giovannucci E, Willett WC, Dietrich T, Dawson-Hughes B. Estimation of optimal serum concentrations of 25-hydroxyvitamin D for multiple health outcomes. Am J Clin Nutr. 2006;84(1):18-28. (Pubitemid 44699167)
102. Dawson-Hughes B, Heaney RP, Holick MF, Lips P, Meunier PJ, Vieth R. Estimates of optimal vitamin D status. Osteoporos Int. 2005;16(7):713-6. (Pubitemid 40933586)
103. Giovannucci E, Liu Y, Rimm EB, et al. Prospective study of predictors of vitamin D status and cancer incidence and mortality in men. J Natl Cancer Inst. 2006;98(7):451-9.
104. Aloia JF, Patel M, Dimaano R, et al. Vitamin D intake to attain a desired serum 25-hydroxyvitamin D concentration. Am J Clin Nutr. 2008;87(6):1952-8. (Pubitemid 351872664)